Johnson & Johnson Reports TREMFYA QUASAR Maintenance Study In UC Met Its Primary Endpoint And All Major Secondary Endpoints, Including Highly Statistically Significant Rates Of Endoscopic Remission
Johnson & Johnson Reports TREMFYA QUASAR Maintenance Study In UC Met Its Primary Endpoint And All Major Secondary Endpoints, Including Highly Statistically Significant Rates Of Endoscopic Remission
Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients with moderately to severely active ulcerative colitisa (UC) receiving subcutaneous (SC) TREMFYA (guselkumab) 200 mg every four weeks (q4w) and 45.2 percent (p<0.001) of patients receiving SC TREMFYA 100 mg every eight weeks (q8w) achieved the primary endpoint of clinical remissionb at Week 44 compared to placebo (18.9 percent).1 In additional analyses of patients who were in clinical remission, 67 percent and 71 percent, respectively, were also in endoscopic remission at Week 44 (Mayo endoscopic subscore [MES]= 0), indicating they had normal appearance of intestinal mucosa.2
強生公司今天公佈了三期QUASAR維持研究(摘要 #759)的第一批數據,該數據顯示,50.0%(p
"These data suggest the potential of guselkumab to provide durable, clinical remission and improve important high-bar endpoints such as endoscopic remission to the point of normalization and histologic remission, which represent the kind of progress needed in new treatments for this inflammatory bowel disease," said David T. Rubin, M.D., Chief, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago and lead study investigator.f "The clinical results measured at Week 44 in the QUASAR Maintenance Study suggest that treatment with guselkumab is a promising therapy to help ulcerative colitis patients with challenging symptoms that impact their daily lives."
芝加哥大學胃腸病學、肝病學和營養學系主任、首席研究員戴維·魯賓醫學博士說:“這些數據表明,guselkumab有可能提供持久的臨床緩解並改善重要的高門檻終點,例如內窺鏡緩解至正常化和組織學緩解,這代表了這種炎症性腸病新療法所需的進展。在QUASAR維持研究的第44周測得的臨床結果表明,使用guselkumab進行治療是一種有前途的療法,可以幫助具有挑戰性症狀並影響其日常生活的潰瘍性結腸炎患者。”
譯文內容由第三人軟體翻譯。